血型CD59基因在胰腺癌中的表达及临床意义

doi:10.3969/j.issn.1671-2587.2024.01.016

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (1): 101-109.DOI: 10.3969/j.issn.1671-2587.2024.01.016

血型CD59基因在胰腺癌中的表达及临床意义

周仁龙¹, 黄国清¹, 李凌波², 唐丹丹³

¹深圳市龙华区中心医院输血科,广东 518110;
²吉林省健康管理学会、深圳爱康生物科技股份有限公司;
³深圳市南山区医疗集团总部,广东 518055

收稿日期:2023-12-01 发布日期:2024-03-13
通讯作者: 唐丹丹,主要从事输血与肿瘤的相关基础研究,（E-mail）1024129289@qq.com。
作者简介:周仁龙,主要从事血型与疾病相关的基础研究,（E-mail）942322151@qq.com。并列第一作者：黄国清,主要从事输血相关基础研究,（E-mail）522415654@qq.com。并列第一作者：李凌波,主要从事血液免疫学相关研究,（E-mail）109738086@qq.com。

Expression and Clinical Significance of Blood Group CD59 Gene in Pancreatic Cancer

ZHOU Renlong¹, HUANG Guoqing¹, LI Lingbo², TANG Dandan³

¹Department of Blood Transfusion, Longhua District Central Hospital, Shenzhen, Guangdong 518110;
²Aikang MedTech Co., Ltd;
³Headquarters of Nanshan Medical Group, Shenzhen, Guangdong 518055

Received:2023-12-01 Published:2024-03-13

摘要/Abstract

摘要： 目的运用生物信息学技术分析CD59血型基因在胰腺癌（pancreatic adenocarcinoma,PAAD）中的表达水平以及临床意义。方法通过GEPIA、UALCAN和HPA数据库分析PAAD中CD59的mRNA和蛋白表达水平。通过TIMER数据库分析CD59在PAAD中与免疫细胞浸润的相关性。通过UALCAN数据库分析CD59参与信号通路影响PAAD的进展。通过STRING数据库分析CD59表达与上下游蛋白的相互作用。基于单因素Cox,多因素Cox回归结果分析CD59血型与PAAD预后相关。结果与癌旁组织相比,CD59在PAAD中的mRNA和蛋白表达水平显著升高（P<0.05）,与CD59低表达PAAD患者相比,高表达CD59的患者预后差。CD59在PAAD中表达水平与CD8+ T细胞,巨噬细胞、中性粒细胞、树突状细胞呈正相关（P<0.05）。基于单因素Cox和多因素Cox回归分析高表达CD59是PAAD预后危险因素。KEGG富集分析占主导地位的是补体和凝血级联通路,GO富集分析占主导地位的是蛋白质加工的调控信号通路。结论 CD59血型基因在PAAD中呈现高表达,与PAAD的发生、发展和预后不良相关,有望作为PAAD诊断、预后判断和治疗靶点。

关键词: 胰腺癌, 生物信息学, CD59基因, 数据库

Abstract: Objective To investigate the expression levels and clinical significance of the CD59 blood type gene in pancreatic adenocarcinoma (PAAD) using bioinformatics techniques. Methods CD59 mRNA and protein expression in PAAD were analyzed via GEPIA, UALCAN, and HPA databases. The TIMER database was utilized to examine the correlation between CD59 in PAAD and immune cell infiltration, UALCAN database to investigate how CD59 in PAAD affected signaling pathways influencing PAAD progression, STRING database to explore the interaction between CD59 expression and upstream/downstream proteins, and Single-factor Cox and multi-factor Cox regression results to assess the association between CD59 blood type and PAAD prognosis. Results mRNA and protein expression levels of CD59 were significantly elevated in PAAD compared to adjacent tissues (P<0.05). Patients with high CD59 expression had a poorer prognosis than those with low CD59 expression in PAAD. The expression of CD59 in PAAD correlated positively with CD8+ T cells, macrophages, neutrophils, and dendritic cells (correlation coefficient>0, P<0.05). Single-factor and multi-factor Cox regression analyses established high CD59 expression as a risk factor for PAAD prognosis. KEGG enrichment analysis revealed a predominant role of the complement and coagulation cascades, while GO enrichment analysis indicated the dominance of regulatory signaling pathways in protein processing. Conclusion The CD59 blood type gene exhibits higher expression in PAAD and correlation with its occurrence, development, and adverse prognosis, suggesting its potential as a diagnostic/prognostic indicator and therapeutic target for PAAD.

Key words: Pancreatic cancer, Bioinformatics, CD59 gene, Database

中图分类号:

R735.9R457.1⁺1

周仁龙, 黄国清, 李凌波, 唐丹丹. 血型CD59基因在胰腺癌中的表达及临床意义[J]. 临床输血与检验, 2024, 26(1): 101-109.

ZHOU Renlong, HUANG Guoqing, LI Lingbo, TANG Dandan. Expression and Clinical Significance of Blood Group CD59 Gene in Pancreatic Cancer[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 101-109.

参考文献

[1] SIEGEL R L,MILLER K D,WAGLE N S,et al.Cancer statistics,2023[J].CA A Cancer J Clin,2023,73(1):17-48.
[2] CHI H,PENG G G,WANG R,et al.Cuprotosis programmed-cell-death-related lncRNA signature predicts prognosis and immune landscape in PAAD patients[J].Cells,2022,11(21):3436.
[3] CHEN X,YUAN Q H,LIU J F,et al.Comprehensive characterization of extracellular matrix-related genes in PAAD identified a novel prognostic panel related to clinical outcomes and immune microenvironment:a silico analysis with in vivo and vitro validation[J].Front Immunol,2022,13:985911.
[4] YAN C,NIU Y D,LI F,et al.System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma[J].J Transl Med,2022,20(1):455.
[5] 中华人民共和国国家卫生健康委员会医政医管局. 胰腺癌诊疗指南(2022年版)[J]. 中华消化外科杂志,2022,21(9):1117-1136.
[6] 汪栋,崔铭,余俊.胰腺癌精准治疗的研究进展[J].中华消化外科杂志,2021,20(4):385-394.
[7] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2020[J].CA A Cancer J Clin,2020,70(1):7-30.
[8] LI X Y,GUO R,LU J,et al.Causality-driven graph neural network for early diagnosis of pancreatic cancer in non-contrast computerized tomography[J].IEEE Trans Med Imaging,2023,42(6):1656-1667.
[9] YAN Y Q,GAO R L,TRINH T L P,et al.Immunodeficiency in pancreatic adenocarcinoma with diabetes revealed by comparative genomics[J].Clin Cancer Res,2017,23(20):6363-6373.
[10] BRUNI D,ANGELL H K,GALON J.The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy[J].Nat Rev Cancer,2020,20(11):662-680.
[11] 李娇,李晓丰,李剑平.CD59缺失的研究进展[J].中国输血杂志,2019,32(2):212-216.
[12] 付宁,仵红娇,谢俞宁,等.CD55启动子区多态性与直肠癌发病风险的研究[J].实用医学杂志,2019,35(18):2886-2890.
[13] 王卫东,董婧珂,龚永生,等.基于生物信息学分析探讨CD59在肺癌中的表达及其临床意义[J].生命科学研究,2022,26(4):361-369.
[14] 孙伟,耿排力.CD59在胃癌中的表达及其生物学意义[J].青海医学院学报,2007,28(1):1-5.
[15] 叶小英,李树中,李中华,等.CD59-血型抗原的研究新进展[J].临床血液学杂志,2019,32(6):487-489.
[16] 顾勇,杨艳,尚玉龙,等.CD46 CD55 CD59在结肠癌组织中的表达及意义[J].中国肿瘤临床,2015,42(6):329-335.
[17] BABIKER A A,NILSSON B,RONQUIST G,et al.Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack[J].Prostate,2005,62(2):105-114.
[18] SHI X X,ZHANG B,ZANG J L,et al.CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer[J].Cell Mol Immunol,2009,6(1):61-66.
[19] TANG Z F,LI C W,KANG B X,et al.GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.
[20] LIU T,YANG K,CHEN J M,et al.Comprehensive pan-cancer analysis of KIF18A as a marker for prognosis and immunity[J].Biomolecules,2023,13(2):326.
[21] HOU W Y,KONG L W,HOU Z P,et al.CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer[J].BMC Med Genomics,2022,15(1):225.
[22] MA J L,CHEN C,LIU S,et al.Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis[J].Cancer Gene Ther,2022,29(11):1578-1589.
[23] SZKLARCZYK D,KIRSCH R,KOUTROULI M,et al.The STRING database in 2023:protein-protein association networks and functional enrichment analyses for any sequenced genome of interest[J].Nucleic Acids Res,2023,51(D1):D638-D646.
[24] WERBA G,WEISSINGER D,KAWALER E A,et al.Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment[J].Nat Commun,2023,14(1):797.
[25] RAHIB L,WEHNER M R,MATRISIAN L M,et al.Estimated projection of US cancer incidence and death to 2040[J].JAMA Netw Open,2021,4(4):e214708.
[26] SARDAR M,RECIO-BOILES A,MODY K,et al.Pharmacotherapeutic options for pancreatic ductal adenocarcinoma[J].Expert Opin Pharmacother,2022,23(18):2079-2089.
[27] 袁慧,李萍萍,张灵敏.基于数据库分析NOX4基因在胰腺癌中的表达及预后[J].现代肿瘤医学,2019,27(19):3460-3465.
[28] 黄彬亮,谢钊敏,王丹,等.广东潮汕地区恶性肿瘤与ABO血型的相关性分析[J].中国输血杂志,2023,36(3):254-257.
[29] AL-SAWAT A,ALSWAT S,ALOSAIMI R,et al.Relationship between ABO blood group and the risk of colorectal cancer:a retrospective multicenter study[J].J Clin Med Res,2022,14(3):119-125.
[30] UWAEZUOKE S N,EZE J N,AYUK A C,et al.ABO histo-blood group and risk of respiratory atopy in children:a review of published evidence[J].Pediatric Health Med Ther,2018,9:73-79.
[31] ENGLISCH C,MOIK F,NOPP S,et al.ABO blood group type and risk of venous thromboembolism in patients with cancer[J].Blood Adv,2022,6(24):6274-6281.
[32] TANAKA Y,KUMAGI T,TERAO T,et al.ABO blood type and the long-term outcomes of pancreatic cancer[J].Intern Med,2020,59(6):761-768.
[33] LIU F F,LI C,ZHU J,et al.ABO blood type and risk of hepatocellular carcinoma:a meta-analysis[J].Expert Rev Gastroenterol Hepatol,2018,12(9):927-933.
[34] SUN X J,AI L,FENG Y C.The value of ABO blood group and complete blood count for the prognosis analysis of gastric cancer patients[J].Onco Targets Ther,2020,13:4627-4633.
[35] 杨孝亮,周小琴,李静,等.胰腺癌患者ABO血型分布相关性研究[J].中国输血杂志,2023,36(2):152-155.
[36] YAN B,LI Y,MIN S J,et al.Effects of the bone/bone marrow microenvironments on prostate cancer cells and CD59 expression[J].Biomed Res Int,2020,2020:2753414.
[37] LI B,CHU X M,GAO M H,et al.The effects of CD59 gene as a target gene on breast cancer cells[J].Cell Immunol,2011,272(1):61-70.
[38] LANGER H F,CHUNG K J,ORLOVA V V,et al.Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis[J].Blood,2010,116(22):4395-4403.
[39] FISHELSON Z,DONIN N,ZELL S,et al.Obstacles to cancer immunotherapy:expression of membrane complement regulatory proteins (mCRPs) in tumors[J].Mol Immunol,2003,40(2/3/4):109-123.
[40] YU L,WEI J,LIU P D.Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer[J].Semin Cancer Biol,2022,85:69-94.
[41] FU M Y,HU Y,LAN T X,et al.The Hippo signalling pathway and its implications in human health and diseases[J].Signal Transduct Target Ther,2022,7(1):376.

血型CD59基因在胰腺癌中的表达及临床意义

Expression and Clinical Significance of Blood Group CD59 Gene in Pancreatic Cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	周仁龙, 钟靖, 唐丹丹. Kidd血型相关SLC14A1基因在肾透明细胞癌中的表达及临床意义[J]. 临床输血与检验, 2024, 26(1): 92-100.
[2]	郭彬瀚, 叶萍, 陈剑, 凤婧, 江咏梅. 基于生物信息学探究红细胞储存时间对子宫内膜癌的影响[J]. 临床输血与检验, 2023, 25(6): 789-797.
[3]	夏悦昕, 刘志远, 宋文倩, 邵林楠, 梁晓华, 周世航. 先天性纯红细胞再生障碍性贫血氧化应激相关差异表达基因的生物信息学分析[J]. 临床输血与检验, 2023, 25(1): 82-87.
[4]	郑艳, 张茜, 孙菲. 敲低S100A1通过降低WNT/β-catenin信号活性抑制甲状腺癌SW579细胞增殖[J]. 临床输血与检验, 2021, 23(2): 146-152.
[5]	朱永明. 血液工作的总目标与当前的一些主要问题[J]. 临床输血与检验, 2021, 23(1): 6-10.
[6]	陈姜, 向洪洲, 李政, 张莹. STAT3在胰腺癌辅助诊断及预后中的价值^*[J]. 临床输血与检验, 2020, 22(2): 156-160.
[7]	蔡晓谕, 林洁, 王超, 关晓珍, 徐振华, 程世军, 汪德清, 李刚. 多中心临床术前贫血数据库构建[J]. 临床输血与检验, 2019, 21(4): 337-340.